GLP-1 & compounded medication availability in Kansas (2026)
Kansas is a steady, by-the-book state for telehealth-prescribed compounded medications: its pharmacy regulator publishes guidance that tracks the federal framework, most recently updated in April 2025 for GLP-1 and GIP products, and leaves it there. Here is the full ten-line picture for Kansas addresses, with that guidance cited below.
What ships to Kansas: all ten lines
| Product line | Available in Kansas? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Ships under a patient-specific prescription with documented clinical reason. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | One national price at every dose. |
| NAD+ | Yes | 8–10 business days | Same ordering flow as the weight-loss lines. |
| Sermorelin | Yes | 8–10 business days | Ships from licensed partner pharmacies. |
| Glutathione | No | N/A | Not something OrderlyMeds offers today. |
| BPC-157 | Yes | 8–10 business days | Compounded injectable; the federal record is below. |
| TB-500 | Yes | 8–10 business days | Compounded injectable. Section below. |
| KPV | No | N/A | Not carried; peptide lines here are injectables only. |
| Epitalon | Yes | 8–10 business days | Compounded injectable; federal status below. |
| MOTS-c | Yes | 8–10 business days | Compounded injectable whose federal record is its own, below. |
An honest “No” beats a padded catalog. Kansas facts on this page were last reviewed on November 16, 2026.
Research peptides in Kansas: BPC-157, TB-500, KPV, Epitalon & MOTS-c
Of these five lines, four ship to Kansas addresses as compounded injectables under patient-specific prescriptions: BPC-157, TB-500, Epitalon and MOTS-c. KPV does not, because our peptide lines are compounded as injectables only. The sections below give each substance its own federal record. The facts differ from one peptide to the next, and they apply to Kansas buyers the same as anywhere.
BPC-157 in Kansas
Available to Kansas addresses as a compounded injectable, filled on a patient-specific prescription. Both federal facts below are part of the deal.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in Kansas
Ships to Kansas addresses as a compounded injectable under a patient-specific prescription. Its federal record follows.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in Kansas
Not available from OrderlyMeds in Kansas or anywhere else, because our peptide lines are injectables and KPV is not one of ours.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in Kansas
In our Kansas formulary as a compounded injectable under a patient-specific prescription. The facts below do not change at the state line.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in Kansas
MOTS-c ships to Kansas addresses as a compounded injectable on a patient-specific prescription. Its federal record below stands on its own.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Kansas’s pharmacy regulators say about compounded medications
Kansas handles compounded medications the way it handles most pharmacy questions: by restating the federal framework in its own guidance and expecting licensees to follow it. The state’s regulator published a GLP-1 statement and updated it in April 2025; it adds documentation and ingredient-form expectations but no Kansas-only layer on top of federal law, and it says nothing singular about the other lines on this page.
The board’s Statement on Compounding and Dispensing of Compounded GLP-1 and GIP Receptor Agonists — guidance the board updated April 17, 2025 — states that compounding drug products that are essentially copies of a commercially available drug product is prohibited unless the drug appears on FDA’s shortage list or a documented, specific change serves an identified patient whose medical needs cannot be met by the commercially available product (a lactose allergy is the board’s own example), and that compounders must use a drug form FDA has approved — not a salt form, and not research-only material. Source: Kansas Board of Pharmacy — Reports & Guidance Documents.
Out-of-state pharmacies shipping prescriptions to Kansas patients must register with the board as nonresident pharmacies before dispensing into the state. Source: Kansas Board of Pharmacy.
Kansas permits prescribing on the basis of a telemedicine encounter under the Kansas Telemedicine Act, which holds telemedicine prescribing to the same standard of care that applies to in-person treatment. Source: Center for Connected Health Policy (CCHP) Policy Finder.
The ordering path for a Kansas patient is the standard one: online eligibility check, telemedicine evaluation with a Kansas-licensed provider, fulfillment by a registered partner pharmacy under a patient-specific prescription with the clinical reason documented, which is exactly what the April 2025 guidance expects a compounder to keep. Pricing does not change at the state line; the pricing page’s number is the Kansas number.
Kansas availability FAQs
Is compounded semaglutide available in Kansas?
Yes. OrderlyMeds ships compounded semaglutide to Kansas addresses under a patient-specific prescription, with the clinical reason documented as the state regulator’s April 2025 guidance expects. New customers start at $74/month for the first two months.
Can a Kansas prescription really start over telemedicine?
Yes. The Kansas Telemedicine Act puts a telemedicine evaluation on the same standard-of-care footing as an office visit, and that is how every OrderlyMeds evaluation works. The cited regulator section above has the detail.
Can I get BPC-157 or other research peptides shipped to Kansas?
BPC-157, TB-500, Epitalon and MOTS-c all ship to Kansas addresses as compounded injectables under patient-specific prescriptions. KPV does not, because injectables only is our rule for these lines. Each substance’s own federal record, including FDA’s safety position, sits in its section above.
How long does delivery to Kansas take?
8–10 business days from signup is the published window for Kansas addresses.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
